Atherosclerosis: Successes, Surprises, and Future Challenges by Libby, Peter et al.
Atherosclerosis: Successes,
Surprises, and Future Challenges
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Libby, Peter, Karin E. Bornfeldt, and Alan R. Tall. 2016.
“Atherosclerosis: Successes, Surprises, and Future Challenges.”
Circ Res 118 (4) (February 18): 531–534. doi:10.1161/
circresaha.116.308334.
Published Version doi:10.1161/CIRCRESAHA.116.308334
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:28547763
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Open Access Policy Articles, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#OAP
		 1	
	
Introductory	article	for	the	atherosclerosis	compendium	for	Circulation	
Research	February	2016	
	
Atherosclerosis	-	successes,	surprises,	and	future	challenges	Peter	Libby*,1	Karin	Bornfeldt*,2	Alan	Tall*3			
*All	three	authors	contributed	equally	to	this	manuscript		1	Cardiovascular	Medicine,	Brigham	and	Women’s	Hospital,	Boston,	Massachusetts	
2	Department	of	Medicine,	Division	of	Metabolism,	Endocrinology	and	Nutrition,	and	Department	of	Pathology,	UW	Diabetes	Institute,	University	of	Washington,	Seattle	WA	98109	
3 Division	of	Molecular	Medicine,	Department	of	Medicine,	Columbia	University,	New	York,	NY	10032		Address	for	correspondence:		Peter	Libby,	Division	of	Cardiovascular	Medicine,	Department	of	Medicine,	Brigham	and	Women's	Hospital,	Harvard	Medical	School,	77	Avenue	Louis	Pasteur,	Boston,	MA	02115;	Phone:	(617)	525-4383;	Fax:	(617)	525-4400;	E-mail:	plibby@rics.bwh.harvard.edu	
		 2	
Many	expected	that	the	splendid	and	remarkable	success	of	statins	and	other	preventive	measures	introduced	towards	the	end	of	the	20th	century	would	halt	the	epidemic	of	atherosclerotic	cardiovascular	disease.1	Yet,	rather	than	receding	globally,	the	burden	of	ischemic	cardiovascular	conditions	has	risen	to	become	a	top	cause	of	morbidity,	loss	of	useful	life	years,	and	mortality	worldwide.2	As	developing	countries	have	undergone	the	"epidemiologic	transition,"	communicable	diseases	have	receded,	and	chronic	diseases,	notably	those	due	to	atherosclerosis	and	hypertension,	have	become	dominant	public	health	problems,	like	in	the	United	States	and	Europe,	as	discussed	in	this	compendium.3	4		Even	with	access	to	the	highest	technology	and	most	recently	available	secondary	prevention	therapies,	the	burden	of	recurrent	events	following	acute	coronary	syndromes	remains	unacceptable,	on	the	order	of	10%	in	the	first	12	months	despite	optimal	treatment	with	contemporary	intervention	and	pharmacologic	agents.5-7	Thus,	on	a	clinical	basis	and	as	a	public	health	challenge,	atherosclerosis	remains	high	on	the	list	of	global	challenges	to	long	and	healthy	lives.		Simultaneously,	laboratory	research	has	continued	to	unravel	successive	layers	of	the	pathophysiology	of	atherosclerosis	and	the	mechanisms	of	its	clinical	complications.	These	advances	have	not	only	deepened	our	appreciation	for	the	subtlety	of	atherogenesis,	they	have	also	provided	us	with	many	surprises	that	have	challenged	numerous	previously	cherished	notions,	and	have	allowed	the	development	of	new	therapeutic	approaches	to	combat	cardiovascular	disease.		Hence	the	need	for	a	compendium	of	articles	that	reviews	the	current	state-of-the-art	of	atherosclerosis	research	spanning	from	a	global	health	perspective	to	fundamental	molecular	mechanisms.	The	editors	intend	this	collection	of	articles	not	only	to	celebrate	the	successes,	but	also	to	highlight	the	emerging	challenges	to	many	tenets	of	belief	that	have	emerged	from	recent	studies.	We	do	so	in	the	spirit	of	inspiring	future	research	to	attack	the	unresolved	questions	and	to	exploit	the	
		 3	
newer	discoveries	that	have	opened	unanticipated	horizons	of	understanding	and	raised	novel	questions	and	opportunities	for	therapies.		Herrington	and	colleagues	lead	off	the	compendium	with	an	update	of	the	epidemiology	of	atherosclerosis,	the	changing	face	of	atherothrombotic	disease	in	the	clinic,	and	the	global	reach	of	this	epidemic.4	Nordestgaard	then	discusses	emerging	epidemiologic	findings	regarding	lipoprotein	risk	factors,	highlighting	new	genetic,	epidemiologic,	and	mechanistic	information	regarding	the	importance	of	triglyceride	and	cholesterol-rich	remnant	lipoproteins.8		The	last	several	decades	witnessed	an	era	of	smaller	studies	that	assessed	the	association	of	single	nucleotide	polymorphisms	with	atherosclerotic	cardiovascular	disease.	This	approach	yielded	little	fruit,	as	few	if	any	of	the	results	proved	generalizable	or	replicable.9	The	advent	of	more	comprehensive	approaches	such	as	genome–wide	association	scans	(GWAS)	and	Mendelian	randomization	analyses	ushered	in	a	new	era	that	has	provided	reproducible,	and	in	some	cases	furnished	eye–opening,	results.	Contemporary	genetics	has	buttressed	the	causal	role	of	low-density	lipoprotein	(LDL)	in	atherogenesis,	but	also	identified	new	targets	that	may	revolutionize	the	therapy	of	this	risk	factor.	The	review	by	McPherson	and	Thyberg–Hansen	summarizes	some	of	the	advances	in	the	genetics	of	coronary	heart	disease	(CHD).10		Kathiresan	and	Musunuru	highlight	surprises	that	have	arisen	from	genetic	analyses	of	lipid	risk	factors,	providing	an	independent	support	for	some	of	the	epidemiologic	findings	presented	by	Nordestgaard.11	Some	of	the	genetic	factors	that	have	emerged	from	contemporary	analyses	affirm	risk	factors	previously	recognized	as	pathogenic	based	on	prior	knowledge,	such	as	increased	levels	of	LDL	cholesterol,	triglycerides,	and	hypertension.	Yet,	there	is	little	or	no	overlap	between	the	lists	of	single	nucleotide	polymorphisms	(SNPs)	associated	with	HDL	cholesterol,	type	2	diabetes,	or	chronic	kidney	disease	and	those	linked	to	CHD,	a	conundrum	that	remains	largely	unexplained.		
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Furthermore,	approximately	75%	of	the	CHD	SNPs	occur	in	or	near	genes	with	no	obvious	connections	to	atherothrombosis,	and	the	relevant	genes	and	their	functions	remain	obscure.	While	holding	promise	for	the	identification	of	new	pathways	and	targets	for	treatment,	the	challenge	of	linking	genetic	variants	to	biological	functions	and	therapeutics	represents	a	significant	hurdle.	Rader	and	colleagues	outline	approaches	to	linking	SNPs	to	genes	and	their	functions,	including	new	tools	from	genomics	and	novel	experimental	approaches	in	cells	and	animals.12	They	discuss	a	few	specific	examples	where	GWAS	“hits”	have	led	to	new	insights	into	the	role	of	specific	genes	in	atherogenesis.	For	the	most	part,	however,	the	new	genetic	information	lacks	integration	into	the	cell	biology	of	atherosclerosis.		Pursuing	the	biological	implications	of	the	emerging	genetic	results	represents	a	promising	area	for	future	investigation.		The	availability	of	validated	genetic	markers	has	raised	the	possibility	of	their	clinical	application	in	risk	stratification	and	to	targeting	therapy	in	a	personalized	or		precision	medicine	mode.	Indeed,	as	discussed	by	McPherson	and	Tybjaerg-Hansen,	genetic	risk	scores	may	predict	who	will	benefit	most	from	statin	therapy.10,	13	Paynter	and	colleagues	provide	a	broad	and	balanced	discussion	of	the	current	utility	and	challenges	of	the	application	of	genetics	in	the	clinic,	including	the	usefulness	of	genetic	information	in	risk	prediction	and	pharmacogenomic	determinants	of	the	response	to	therapies	for	atherothrombosis.14			Advances	in	the	cell	biology	of	atherosclerosis	and	its	pathogenesis	have	also	yielded	advances	and	surprises.	The	endothelial	cell,	relegated	to	a	gatekeeper	barrier	function	for	much	of	the	last	century,	has	emerged	as	the	defender	of	vascular	homeostasis	as	described	by	Gimbrone	and	Garcia-Cardeña	in	a	masterful	review	that	covers	the	history	of	contemporary	endothelial	biology	in	the	context	of	atherogenesis,	and	brings	us	up	to	date	with	the	latest	discoveries	in	this	regard.15	Endothelial	dysfunction	in	atherosclerosis	extends	beyond	impaired	vasodilator	capacity,	and	also	involves	disturbances	in	anti-thrombotic,	pro-fibrinolytic,	and	anti-inflammatory	and	anti-oxidant	properties	of	the	normal	endothelium.	
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We	have	learned	that	the	myeloid	cells	involved	in	atherosclerosis	have	functionally	important	diversity.	These	foot	soldiers	of	the	innate	immune	response	may	also	instruct	the	adaptive	immune	system.	The	delicate	duet	between	innate	and	adaptive	immunity	likely	provides	major	modulatory	influences	on	the	disease.	The	contributions	of	Cybulsky	and	colleagues,16	Tabas	and	Bornfeldt,17	and	Ketelhuth	and	Hansson18	delve	into	the	intricacies	of	cellular	and	humoral	immunity	and	of	myeloid	cells	and	mononuclear	phagocytes.	In	particular,	Cybulsky,	Cheong,	and	Robbins	contrast	the	functional	palettes	of	monocytes,	macrophages	residing	in	the	adventitial	versus	intimal	layers	of	arteries,	and	dendritic	cells,	in	atherosclerosis.16	They	underline	the	need	for	the	use	of	multiple	cell	surface	markers,	transcription	factor	expression,	and	transcriptional	profiling	to	distinguish	and	understand	functionally	distinct	cell	populations.		Tabas	and	Bornfeldt	highlight	the	fates	of	these	important	cells	in	different	stages	of	atherosclerosis.17	They	review	the	functional	programs	and	roles	of	lesional	macrophages,	and	argue	that	mononuclear	phagocytes	functions	reflect	the	microenvironment	in	the	atheroma.	They	argue	that	the	field	has	moved	beyond	this	relatively	simple	boxing	of	macrophage	functions	into	“M1”	and	“M2”	categories.		Rather,	macrophage	character	depends	on	a	plethora	of	pro-	and	anti-inflammatory	mediators	present	in	lesions,	which	involve	multiple	signal	transduction	pathways	and	downstream	effects	in	macrophages,	leading	to	increased	inflammatory	activation	or	resolution	of	the	inflammatory	process.	Macrophage	functions	also	depend	on	the	balance	of	lipids	in	different	cellular	compartments,	and	the	metabolic	demands	on	the	macrophage.	The	different	functional	attributes	of	macrophages	influence	the	initiation	of	lesions,	their	progression	to	advanced	atheromata,	their	complication,	and	their	responses	to	therapies.		The	review	provided	by	Sorci-Thomas	and	Thomas	highlights	the	interface	between	immune	cell	lipid	loading,	cellular	cholesterol-rich	membrane	microdomains,	and	inflammation.19	Recent	research	has	revealed	dynamic	regulation	of	the	balance	between	free	cholesterol	in	cellular	membrane	microdomains	and	esterified	
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cholesterol	in	lipid	droplets,	in	part	governed	by	lipoproteins	and	cellular	cholesterol	exporters.	Increased	free	cholesterol	in	immune	cells	provides	important	links	to	inflammation	by	promoting	receptor	over-sensitization,	leading	to	hematopoietic	stem	cell	proliferation,	leukocytosis,	and	T	cell	activation.	These	links	among	lipoproteins,	cellular	cholesterol,	and	inflammation	likely	influence	not	only	atherosclerosis	but	also	autoimmune	diseases.	Together,	the	recent	discoveries	related	to	myeloid	cells	and	other	immune	cells	involved	in	atherosclerosis	have	highlighted	potential	targets	for	therapeutic	intervention	ranging	from	vaccination	to	anti–cytokine	treatments.		The	study	of	smooth	muscle	cells,	traditionally	considered	a	specialized	relative	of	fibroblasts,	has	also	yielded	surprises.20	Recent	results	have	raised	important	questions	about	the	very	identity	of	smooth	muscle	cells,	and	suggested	unanticipated	transmutability	between	cells	that	we	have	traditionally	labeled	as	vascular	smooth	muscle	cells	and	mononuclear	leukocytes.	These	recent	findings	provide	a	stark	contrast	with	previous	notions.	Much	work	in	the	last	quarter	of	the	20th	century	focused	on	smooth	muscle	cell	proliferation	and	even	proposed	a	monoclonal	or	monotypic	replication	of	the	cells	as	paramount	in	atherogenesis,	a	notion	quite	contrary	to	the	current	recognition	of	the	developmental	and	functional	diversity	of	these	cells.21	Early	formulations	of	the	“response	to	injury”	hypothesis	of	atherogenesis	viewed	it	as	a	bland	process	rooted	in	inappropriate	proliferation	of	smooth	muscle	cells.22,	23	Bennett,	Sinha,	and	Owens	provide	a	fascinating	review	of	new	concepts	in	vascular	smooth	muscle	cell	biology	in	relation	to	atherosclerosis.	They	explicate	the	dynamic	and	diverse	properties	of	smooth	muscle	cells,	including	smooth	muscle	cell	embryological	origin,	phenotype	switching,	conversion	of	smooth	muscle	cells	to	macrophage-like	cells,	and	the	roles	of	smooth	muscle	cell	proliferation,	apoptosis,	and	senescence	in	different	phases	of	atherosclerosis.20	Smooth	muscle	cell	biology	has	regained	a	central	place	at	the	cutting	edge	of	atherosclerosis	research.			
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Results	of	recent	laboratory	studies	have	uncovered	regulatory	mechanisms	pertinent	to	atherogenesis	undreamed	of	only	a	few	decades	ago.	The	role	of	non-coding	small	RNAs	(micro-RNAs)	as	“fine-tuners”	of	atherosclerotic	progression	and	regression	and	lipid	metabolism	has	opened	entirely	new	vistas	on	the	molecular	pathways	that	control	this	disease,	as	reviewed	by	Feinberg	and	Moore.24	As	in	the	case	of	mRNAs,	cytokines,	shear-stress,	and	other	atherogenic	mediators	regulate	micro-RNA	concentrations.	Micro-RNAs	control	all	major	cell	types	involved	in	atherosclerosis,	and	participate	in	cell-to-cell	communication.	Furthermore,	emerging	research	suggests	that	plasma	micro-RNAs	can	serve	as	biomarkers	of	cardiovascular	disease	diagnosis,	prognosis,	and	pharmacological	treatment	effectiveness.	The	coming	years	are	certain	to	bring	new	and	exciting	discoveries	related	to	non-coding	RNAs	and	RNA	therapeutics	with	respect	to	atherosclerosis.			From	a	therapeutic	standpoint,	we	have	much	to	celebrate,	and	much	to	anticipate.		Harnessing	the	results	of	experimental	laboratory	research	may	yield	even	further	advances	in	treatments.	Pedersen	describes	from	an	"eye–witness"	perspective	the	success	story	of	LDL	cholesterol	lowering.25	Shapiro	and	Fazio	look	beyond	statins,	and	discuss	new	avenues	to	reducing	atherosclerotic	risk	not	only	by	targeting	lipids	with	novel	interventions,	but	also	by	reaching	beyond	targeting	traditional	risk	factors	to	new	approaches	based	on	anti-inflammatory	therapies.	26		To	guide,	inform,	and	validate	novel	therapies	Rudd	and	colleagues	contribute	a	comprehensive	review	of	the	burgeoning	imaging	approaches	to	the	visualization	of	atherosclerosis.27	Only	a	few	decades	ago,	the	luminogram	visualized	by	arteriography	provided	the	"gold	standard"	for	atherosclerosis	imaging.	We	now	stand	on	the	threshold	of	an	era	where	we	can	not	only	image	the	lesion	itself	rather	than	the	lumen,	but	also	particular	cells,	molecular	mediators,	and	cellular	functions	relevant	to	disease	pathogenesis.		The	advances	described	in	the	articles	included	in	this	compendium	celebrate	the	strides	made	in	understanding	atherosclerosis	in	recent	decades.	We	highlight	the	
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novel,	the	unsuspected,	the	contrarian,	and	the	challenging.	Despite	this	ferment	in	the	field,	many	questions	remain	unanswered	and	provide	fertile	ground	for	future	research.	For	example,	the	simple	notion	that	increasing	HDL	cholesterol	levels	would	consistently	reduce	atherosclerosis	risk	has	faced	challenges	from	disappointing	clinical	trials	and	Mendelian	randomization	analyses.	11	Notwithstanding,	the	ascertainment	of	HDL	functions	such	as	cholesterol	efflux	potential	and	of	HDL	particle	number,	and	therapeutic	approaches	that	increase	these	variables	warrant	continued	investigation.	In	particular,	some	approaches	to	increasing	HDL	function	or	promoting	reverse	cholesterol	transport	using	HDL	mimetics	or	infusions	of	apolipoprotein	A1	or	its	variants	merit	continued	consideration.		New	data	regarding	the	pathogenicity	of	triglyceride-rich	type	lipoproteins	have	rekindled	interest	in	the	functional	roles	of	Apolipoproteins	V	and	C3,	and	the	new	players,	Angptl3	and	Angptl4.11	These	findings	have	stimulated	renewed	efforts	to	target	therapeutically	triglycerides	or	perhaps	more	specifically	cholesterol-rich	remnant	lipoproteins.8	Lipoprotein	(a)	has	emerged	as	a	likely	causative	agent	in	atherothrombosis	from	GWAS	and	Mendelian	randomization	analyses.10		The	accumulating	information	implicating	inflammatory	pathways	as	links	between	traditional	and	emerging	risk	factors	and	atherosclerosis	and	its	complications	have	led	to	trials	that	target	these	pathways	therapeutically.		Large-scale	clinical	outcome	studies	currently	underway	use	a	monoclonal	antibody	that	neutralizes	interleukin	1β	or	weekly	administration	of	low–dose	methotrexate.28,	29		In	view	of	the	redundancy	of	inflammatory	signaling	and	its	importance	in	maintaining	host	defenses,	the	application	of	anti-inflammatory	interventions	may	require	targeted	efforts	to	find	the	"sweet	spot"	that	will	quell	disease–relevant	information	without	impairing	tumor	surveillance	or	defenses	against	infection.	In	this	regard,	harnessing	advances	in	understanding	mediators	of	the	resolution	of	inflammation	that	do	not	per	se	have	anti-inflammatory	actions	merits	further	development.	30	
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	Ultimately,	we	must	strive	to	reach	beyond	the	experimental	laboratory	and	biomarkers	or	observational	studies,	and	test	hypotheses	in	humans	that	have	emerged	from	the	advances	in	basic	research.	The	critical	importance	of	properly	designed	and	powered	clinical	trials	has	become	even	more	evident	given	the	surprises	that	emerge	from	such	undertakings.	Clinical	trials	require	daunting	resources,	as	standard	of	care	therapies	have	reduced	event	rates,	demanding	larger	and	longer	studies	to	demonstrate	incremental	benefit.	We	need	to	extend	clinical	trials	globally,	to	address	the	growing	problem	of	cardiovascular	disease	world-wide.4	We	also	need	to	reach	beyond	a	“one	size	fits	all”	approach	and	to	develop	"smarter"	trial	designs,	including	the	judicious	use	of	biomarkers	and	genetic	information	to	target	therapies	towards	those	who	are	most	likely	to	benefit	from	treatment		to	enhance	their	likelihood	of	success,	and	to	achieve	the	goal	of	precision	medicine	in	the	future	management	of	atherosclerotic	risk	in	our	patients.	We	trust	that	the	papers	assembled	in	this	compendium	will	prove	useful	in	spurring	and	informing	this	future	progress.		
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Figure	legend	
Figure	1.	Interplay	among	processes	associated	with	increased	cardiovascular	
disease	risk	and	treatment	strategies	targeting	these	processes.	The	review	articles	included	in	this	compendium	provide	a	comprehensive	overview	of	the	state	of	the	atherosclerosis	research	area	today	and	some	of	its	history.	Recent	progress	has	advanced	three	major	areas	related	to	atherosclerosis	and	cardiovascular	risk:	the	roles	of	lipoproteins	(LDL,	TG-rich	remnant	lipoproteins	and	HDL);	identification	of	genes	associated	with	cardiovascular	disease	risk	through	GWAS;	
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and	further	elucidation	of	local	processes	in	the	artery	wall.	These	three	areas	exhibit	significant	overlap	as	demonstrated	by	the	Venn	diagram.	Treatment	strategies	targeting	lipoproteins	and	several	of	the	genes	identified	by	GWAS	include	statins	and	the	recently	approved	PCSK9	inhibitors.	Anti-inflammatory	agents	might	target	inflammatory	genes	identified	by	GWAS.	Anti-inflammatory	agents,	as	well	as	anti-hypertensive	agents	may	also	modulate	atherogenic	processes	locally	in	the	artery	wall.		 	
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